Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $20.83

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.83.

A number of research firms have recently issued reports on ZVRA. Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. JMP Securities assumed coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Monday, September 30th. Roth Mkm lifted their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Finally, Guggenheim assumed coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price objective on the stock.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. FMR LLC increased its position in shares of Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. Vanguard Group Inc. raised its position in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after acquiring an additional 58,866 shares during the period. Retirement Planning Co of New England Inc. raised its position in Zevra Therapeutics by 6.5% in the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock worth $2,246,000 after acquiring an additional 28,107 shares during the period. Mystic Asset Management Inc. boosted its stake in Zevra Therapeutics by 11.9% in the second quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock valued at $1,460,000 after acquiring an additional 31,650 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Zevra Therapeutics by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after acquiring an additional 21,231 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $8.66 on Thursday. The firm has a market cap of $455.69 million, a PE ratio of -4.40 and a beta of 1.93. Zevra Therapeutics has a 52-week low of $4.11 and a 52-week high of $9.09. The business’s 50 day moving average price is $7.97 and its two-hundred day moving average price is $6.44. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period in the prior year, the company earned ($0.15) earnings per share. On average, equities analysts anticipate that Zevra Therapeutics will post -1.63 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.